J. Rossouw, G. Anderson, R. Prentice, A. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, Jama, vol.288, pp.321-333, 2002.

G. Anderson, M. Limacher, A. Assaf, T. Bassford, S. Beresford et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, Jama, vol.291, pp.1701-1712, 2004.

V. Olie, M. Canonico, and P. Scarabin, Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women, Current Opinion in Hematology, vol.17, issue.5, pp.457-463, 2010.
DOI : 10.1097/MOH.0b013e32833c07bc

P. Scarabin, E. Oger, and G. Plu-bureau, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, The Lancet, vol.362, issue.9382, pp.428-432, 2003.
DOI : 10.1016/S0140-6736(03)14066-4

URL : https://hal.archives-ouvertes.fr/hal-01026273

M. Canonico, E. Oger, G. Plu-bureau, J. Conard, G. Meyer et al., Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study, Circulation, vol.115, issue.7, pp.840-845, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.642280

URL : https://hal.archives-ouvertes.fr/hal-00688234

M. Canonico, A. Fournier, L. Carcaillon, V. Olie, G. Plu-bureau et al., Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.2, pp.340-345, 2010.
DOI : 10.1161/ATVBAHA.109.196022

URL : https://hal.archives-ouvertes.fr/inserm-01142846

C. Renoux, S. Dell-'aniello, and S. Suissa, Hormone replacement therapy and the risk of venous thromboembolism: a population-based study, J Thromb Haemost, vol.8, pp.979-986, 2010.

M. Canonico, G. Plu-bureau, G. Lowe, and P. Scarabin, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, BMJ, vol.336, issue.7655, pp.1227-1231, 2008.
DOI : 10.1136/bmj.39555.441944.BE

URL : https://hal.archives-ouvertes.fr/inserm-01142884

J. Curb, R. Prentice, P. Bray, R. Langer, L. Van-horn et al., Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus, Archives of Internal Medicine, vol.166, issue.7, pp.772-780, 2006.
DOI : 10.1001/archinte.166.7.772

M. Vickers, A. Maclennan, B. Lawton, D. Ford, J. Martin et al., Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women, BMJ, vol.335, issue.7613, p.239, 2007.
DOI : 10.1136/bmj.39266.425069.AD

N. Allen, K. Tsilidis, T. Key, L. Dossus, R. Kaaks et al., Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition, American Journal of Epidemiology, vol.172, issue.12, pp.1394-1403, 2010.
DOI : 10.1093/aje/kwq300

R. Sitruk-ware, Pharmacological profile of progestins, Maturitas, vol.47, issue.4, pp.277-283, 2004.
DOI : 10.1016/j.maturitas.2004.01.001

A. Nath and R. Sitruk-ware, Different cardiovascular effects of progestins according to structure and activity, Climacteric, vol.100, issue.sup1, pp.96-101, 2009.
DOI : 10.1161/hc4801.099737

R. Sitruk-ware, New Progestogens, Drugs & Aging, vol.46, issue.1, pp.865-883, 2004.
DOI : 10.2165/00002512-200421130-00004

E. Daly, M. Vessey, M. Hawkins, J. Carson, P. Gough et al., Risk of venous thromboembolism in users of hormone replacement therapy, The Lancet, vol.348, issue.9033, pp.977-980, 1996.
DOI : 10.1016/S0140-6736(96)07113-9

H. Jick, L. Derby, M. Myers, C. Vasilakis, and K. Newton, Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens, The Lancet, vol.348, issue.9033, pp.981-983, 1996.
DOI : 10.1016/S0140-6736(96)07114-0

S. Perez-gutthann, G. Rodriguez, L. Castellsague, J. Smith, N. Heckbert et al., Hormone replacement therapy and risk of venous thromboembolism: population based case-control study, BMJ, vol.314, issue.7083, pp.796-8001581, 1997.
DOI : 10.1136/bmj.314.7083.796

M. Cushman, L. Kuller, R. Prentice, R. Rodabough, B. Psaty et al., Estrogen Plus Progestin and Risk of Venous Thrombosis, JAMA, vol.292, issue.13, pp.1573-1580, 2004.
DOI : 10.1001/jama.292.13.1573

D. Fraser, M. Padwick, M. Whitehead, J. White, T. Ryder et al., The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy, Maturitas, vol.11, issue.1, pp.21-346, 1989.
DOI : 10.1016/0378-5122(89)90117-5

T. Simon, B. Yon-de-jonage-canonico, M. Oger, E. Wahl, D. Conard et al., Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism, Journal of Thrombosis and Haemostasis, vol.85, issue.1, pp.71-7621, 2003.
DOI : 10.1046/j.1365-2265.1997.2601068.x

URL : https://hal.archives-ouvertes.fr/hal-00688975

S. Cummings, B. Ettinger, P. Delmas, P. Kenemans, V. Stathopoulos et al., The Effects of Tibolone in Older Postmenopausal Women, New England Journal of Medicine, vol.359, issue.7, pp.697-708, 2008.
DOI : 10.1056/NEJMoa0800743

P. Kenemans, N. Bundred, J. Foidart, E. Kubista, V. Schoultz et al., Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial, The Lancet Oncology, vol.10, issue.2, pp.135-146, 2009.
DOI : 10.1016/S1470-2045(08)70341-3

J. Conard, A. Basdevant, J. Thomas, E. Ochsenbein, C. Denis et al., Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol, Fertility and Sterility, vol.64, issue.5, pp.957-962, 1995.
DOI : 10.1016/S0015-0282(16)57909-6

C. Egarter, P. Geurts, E. Boschitsch, P. Speiser, and J. Huber, The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women, Acta Obstetricia et Gynecologica Scandinavica, vol.75, issue.4, pp.386-393, 1996.
DOI : 10.3109/00016349609033337

K. Koh, R. Mincemoyer, M. Bui, G. Csako, F. Pucino et al., Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women, N Engl J Med, vol.3, issue.336, pp.683-690, 1997.

P. Scarabin, M. Alhenc-gelas, G. Plu-bureau, P. Taisne, R. Agher et al., Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women : A Randomized Controlled Trial, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.17, issue.11, pp.3071-3078, 1997.
DOI : 10.1161/01.ATV.17.11.3071

E. Hoibraaten, I. Os, I. Seljeflot, T. Andersen, A. Hofstad et al., The Effects of Hormone Replacement Therapy on Hemostatic Variables in Women with Angiographically Verified Coronary Artery Disease, Thrombosis Research, vol.98, issue.1, pp.19-27, 2000.
DOI : 10.1016/S0049-3848(99)00233-9

H. Teede, B. Mcgrath, J. Smolich, E. Malan, D. Kotsopoulos et al., Postmenopausal Hormone Replacement Therapy Increases Coagulation Activity and Fibrinolysis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.5, pp.1404-140929, 2000.
DOI : 10.1161/01.ATV.20.5.1404

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.619.1709

F. Chen, N. Lee, Y. Soong, and K. Huang, Short-and long-term effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women, Chang Gung Med J, vol.24, pp.431-439, 2001.

A. Demirol, C. Baykal, S. Kirazli, and A. Ayhan, Effects of hormone replacement on hemostasis in spontaneous menopause, Menopause, vol.8, issue.2, pp.135-140, 2001.
DOI : 10.1097/00042192-200103000-00009

A. Gottsater, M. Rendell, U. Hulthen, E. Berntorp, and I. Mattiasson, Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors, Journal of Internal Medicine, vol.2, issue.3, pp.237-246, 2001.
DOI : 10.1016/S0029-7844(96)00530-3

E. Hoibraaten, M. Mowinckel, H. De-ronde, R. Bertina, and P. Sandset, Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial, British Journal of Haematology, vol.147, issue.2, pp.415-420, 2001.
DOI : 10.1016/S0140-6736(99)06092-4

R. Lobo, T. Bush, B. Carr, and J. Pickar, Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism, Fertility and Sterility, vol.76, issue.1, pp.13-24, 2001.
DOI : 10.1016/S0015-0282(01)01829-5

M. Perera, N. Sattar, J. Petrie, C. Hillier, M. Small et al., The Effects of Transdermal Estradiol in Combination with Oral Norethisterone on Lipoproteins, Coagulation, and Endothelial Markers in Postmenopausal Women with Type 2 Diabetes: A Randomized, Placebo-Controlled Study, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.3, pp.1140-11431017, 2001.
DOI : 10.1210/jcem.86.3.7297

M. Post, M. Christella, L. Thomassen, M. Van-der-mooren, W. Van-baal et al., Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.6, pp.1671-16761116, 2003.
DOI : 10.1161/01.ATV.0000074146.36646.C8

J. Stevenson, A. Oladipo, N. Manassiev, M. Whitehead, S. Guilford et al., Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers, British Journal of Haematology, vol.2, issue.3, pp.802-808, 2004.
DOI : 10.1016/S0925-4439(97)00097-5

P. Collins, M. Flather, B. Lees, R. Mister, A. Proudler et al., Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study, European Heart Journal, vol.27, issue.17, pp.2046-2053, 2006.
DOI : 10.1093/eurheartj/ehl183

M. Taner, E. Ozpolat, C. Taskiran, M. Onan, T. Gursel et al., Effects of four different regimens of hormone replacement therapy on hemostatic parameters: A prospective randomized study, Maturitas, vol.53, issue.3, pp.267-273, 2006.
DOI : 10.1016/j.maturitas.2005.05.010

C. Bonduki, D. Lourenco, E. Motta, S. Jr, J. Haidar et al., Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women, Clinics, vol.62, issue.5, pp.553-560, 2007.
DOI : 10.1590/S1807-59322007000500004

J. Endrikat, M. Sandri, C. Gerlinger, A. Rubig, W. Schmidt et al., A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 ??g ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight, The European Journal of Contraception & Reproductive Health Care, vol.97, issue.9, pp.220-228, 2007.
DOI : 10.1080/13625180008500387

L. Norris, J. Brosnan, J. Bonnar, J. Conard, C. Kluft et al., Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors, Thromb Haemost Climacteric, vol.100, issue.11, pp.253-260489, 2008.

N. Smith, J. Wiley, C. Legault, K. Rice, S. Heckbert et al., Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women, Menopause, vol.15, issue.6, pp.1145-1150, 2008.
DOI : 10.1097/gme.0b013e3181775eca

G. Samsioe and J. Hruska, Optimal tolerability of ultra-low-dose continuous combined 17??-estradiol and norethisterone acetate: laboratory and safety results, Climacteric, vol.21, issue.1, pp.34-44, 2010.
DOI : 10.1016/S0015-0282(01)01791-5

M. Canonico, M. Alhenc-gelas, G. Plu-bureau, V. Olie, and P. Scarabin, Activated protein C resistance among postmenopausal women using transdermal estrogens, Menopause, vol.17, issue.6, pp.1122-1127, 2010.
DOI : 10.1097/gme.0b013e3181e102eb

URL : https://hal.archives-ouvertes.fr/inserm-01148711

J. Sidelmann, J. Jespersen, L. Andersen, and S. Skouby, Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study, BJOG: An International Journal of Obstetrics and Gynaecology, vol.83, issue.6, pp.541-547, 2003.
DOI : 10.1046/j.0007-1048.2002.03356.x

U. Winkler, R. Altkemper, B. Kwee, and F. Helmond, Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study, Fertility and Sterility, vol.74, issue.1, pp.10-19, 2000.
DOI : 10.1016/S0015-0282(00)00587-2

L. Norris, M. Joyce, O. Keeffe, N. Sheppard, B. Bonnar et al., Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy, Maturitas, vol.43, issue.2, pp.125-133, 2002.
DOI : 10.1016/S0378-5122(02)00202-5

K. Koh, J. Ahn, D. Jin, B. Yoon, H. Kim et al., Significant Differential Effects of Hormone Therapy or Tibolone on Markers of Cardiovascular Disease in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.10, pp.1889-1894, 2003.
DOI : 10.1161/01.ATV.0000091502.96745.95

K. Koh, S. Han, M. Shin, J. Ahn, Y. Lee et al., Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study, European Heart Journal, vol.26, issue.14, pp.1362-1368, 2005.
DOI : 10.1093/eurheartj/ehi311

A. Eilertsen, E. Qvigstad, T. Andersen, L. Sandvik, and P. Sandset, Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation, Maturitas, vol.55, issue.3, pp.278-287, 2006.
DOI : 10.1016/j.maturitas.2006.04.012

A. Eilertsen, S. Liestol, M. Mowinckel, H. Hemker, and P. Sandset, Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system, Thrombosis and Haemostasis, vol.97, pp.938-943, 2007.
DOI : 10.1160/TH06-11-0632

A. Eilertsen, L. Sandvik, M. Mowinckel, T. Andersen, E. Qvigstad et al., Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis, Thrombosis Research, vol.120, issue.3, pp.371-379, 2007.
DOI : 10.1016/j.thromres.2006.10.013

A. Demirol, S. Guven, G. Guven, E. Kirazli, S. Gurgan et al., Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study, Fertility and Sterility, vol.87, issue.4, pp.842-848, 2007.
DOI : 10.1016/j.fertnstert.2006.08.090